These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32818964)

  • 1. Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia).
    Gómez MA; Navas A; Prieto MD; Giraldo-Parra L; Cossio A; Alexander N; Gore Saravia N
    Clin Infect Dis; 2021 May; 72(10):e484-e492. PubMed ID: 32818964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
    Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiles of Local and Systemic Inflammation in the Outcome of Treatment of Human Cutaneous Leishmaniasis Caused by
    Navas A; Fernández O; Gallego-Marín C; Castro MDM; Rosales-Chilama M; Murillo J; Cossio A; McMahon-Pratt D; Saravia NG; Gómez MA
    Infect Immun; 2020 Feb; 88(3):. PubMed ID: 31818959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
    Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
    Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis.
    Fernández OL; Rosales-Chilama M; Sánchez-Hidalgo A; Gómez P; Rebellón-Sánchez DE; Regli IB; Díaz-Varela M; Tacchini-Cottier F; Saravia NG
    PLoS Negl Trop Dis; 2024 May; 18(5):e0012156. PubMed ID: 38709850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance of
    Regli IB; Fernández OL; Martínez-Salazar B; Gómez MA; Saravia NG; Tacchini-Cottier F
    Front Immunol; 2018; 9():3040. PubMed ID: 30622537
    [No Abstract]   [Full Text] [Related]  

  • 7. Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: impact on intracellular parasite survival.
    Gómez MA; Navas A; Márquez R; Rojas LJ; Vargas DA; Blanco VM; Koren R; Zilberstein D; Saravia NG
    J Antimicrob Chemother; 2014 Jan; 69(1):139-49. PubMed ID: 23975742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.
    Barrera MC; Rojas LJ; Weiss A; Fernandez O; McMahon-Pratt D; Saravia NG; Gomez MA
    Acta Trop; 2017 Dec; 176():355-363. PubMed ID: 28843396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of
    Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
    Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
    Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
    Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
    Demicheli C; Ochoa R; da Silva JB; Falcão CA; Rossi-Bergmann B; de Melo AL; Sinisterra RD; Frézard F
    Antimicrob Agents Chemother; 2004 Jan; 48(1):100-3. PubMed ID: 14693525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
    Moosavian SA; Fallah M; Jaafari MR
    Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
    Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
    J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
    Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis.
    Gonçalves-Oliveira LF; Souza-Silva F; de Castro Côrtes LM; Veloso LB; Santini Pereira BA; Cysne-Finkelstein L; Lechuga GC; Bourguignon SC; Almeida-Souza F; da Silva Calabrese K; Ferreira VF; Alves CR
    Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():101-108. PubMed ID: 31430693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated Leishmaniasis, a Severe Form of Leishmania braziliensis Infection.
    Machado PRL; Lago A; Cardoso TM; Magalhaes A; Carvalho LP; Lago T; Carvalho AM; Costa R; Carvalho EM
    Emerg Infect Dis; 2024 Mar; 30(3):510-518. PubMed ID: 38407142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host's immune response in unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis treated by meglumine antimoniate: A case-control study of Th1 and Th2 pathways.
    Bamorovat M; Sharifi I; Aflatoonian MR; Sadeghi B; Shafiian A; Oliaee RT; Keyhani A; Afshar AA; Khosravi A; Mostafavi M; Parizi MH; Khatami M; Arefinia N
    Int Immunopharmacol; 2019 Apr; 69():321-327. PubMed ID: 30771740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
    Romero GA; Guerra MV; Paes MG; Macêdo VO
    Am J Trop Med Hyg; 2001 Nov; 65(5):456-65. PubMed ID: 11716098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous occurrence of cutaneous and mucocutaneous leishmaniasis caused by different genotypes of Leishmania (Viannia) braziliensis.
    Hoyos CL; Quipildor M; Bracamonte E; Lauthier JJ; Cajal P; Uncos A; Korenaga M; Hashiguchi Y; Barroso PA; Marco JD
    J Dermatol; 2019 Sep; 46(9):e320-e322. PubMed ID: 30938461
    [No Abstract]   [Full Text] [Related]  

  • 20. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
    Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
    J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.